Prakash Agarwal

Prakash Agarwal on India Ratings believes unseasonal rains may affect public sector banks‘ asset quality. Punjab National Bank‘s agri non-performing assets (NPAs) could increase by 6 percent, he added.

Hold Sun Pharmaceutical Industries: Prakash Agarwal

Prakash Agarwal, Equity Analyst at CIMB is of the view that one may hold Sun Pharmaceutical Industries.

Hold Ranbaxy Laboratories, says Prakash Agarwal

According to Prakash Agarwal, Equity Analyst at CIMB, one may hold Ranbaxy Laboratories.

US core business continues to be a drag for Ranbaxy: CIMB

Prakash Agarwal, Equity Analyst, CIMB has a hold rating on Ranbaxy with target price of Rs 630/share.

Reduce rating on DLF, target price at Rs 140: CIMB

Post the Aman Resorts sale, DLF's debt will come down from Rs 19,500 crore to Rs 17,500 crore, says Prakash Agarwal of CIMB

Reduce DLF; target Rs 140: Prakash Agarwal

Prakash Agarwal of CIMB is of the view that DLF may slip to Rs 140.

Aurobindo may see 4% EPS dilution in near term: CIMB

According to Prakash Agarwal of CIMB, the Aurobindo Pharma-Actavis deal seems lucrative on the medium-to-long-term perspective.

Ticket size a concern in Mumbai realty, not demand: CIMB

Prakash Agarwal, Vice-President of CIMB says high debt remains a concern for DLF. He likes Oberoi Realty on the back of good projects. He also has an outperform rating on Sobha Developers

Sobha Developers, Oberoi Realty top pick: Prakash Agarwal

According to Prakash Agarwal, Real Estate Analyst at CIMB, Sobha Developers and Oberoi Realty are the top picks in the real estate space.

Realty recovery cycle still far; pick Shobha, Oberoi: CIMB

Real Estate Analyst, CIMB, Prakash Agarwal's top picks relatively are Sobha Developers because the company has been focusing on project execution – both in terms of completion and sales, along with it being in a better market - that is Bangalore. He is bullish on Oberoi Realty too.

Pharma sector: RBS picks Cipla, Lupin; shuns Dr Reddy's

Prakash Agarwal, Equity Analyst - India Pharma, RBS is positive on Lupin and advises investor to buy on dips. In the largecap space, Cipla is his top pick He has a target price of Rs 371 on the stock. In the midcap space, he likes Glenmark Pharma.

Sell Unitech with target of Rs 30: Prakash Agarwal

Sell Unitech with target of Rs 30, says Prakash Agarwal, Equity Analyst - India Pharma & Property at Royal Bank of Scotland.

Find out what is RBS' call on IBERL, Glenmark

In an exclusive interview with CNBC-TV18’s Latha Venkatesh and Sonia Shenoy, Prakash Agarwal equity analyst at RBS spoke about two hot stocks—Indiabulls Real Estate and Glenmark Pharma.